Extensive-stage Small-cell Lung Cancer
Conditions
Brief summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Interventions
None listed
Sponsors
Hunan Province Tumor Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients must be ≥18 years. * Provision of fully informed consent prior to any study specific procedures. * Patients with extensive stage SCLC diagnosed by pathology (as staged by the American Veterans Lung Cancer Association (VALG)), who do not have an imaging response during first-line treatment with PD-(L)1 inhibitors, or who progress after imaging reactions on first-line therapy (the most recent regimen prior to enrollment must contain PD-(L)1 inhibitors). * According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 2 years | Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 2 years | Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first) |
| OS | 2 years | Defined as the time from the start of treatment to the death of the subject due to any cause. |
Countries
China
Contacts
Primary ContactYongchang Zhang, MD
Backup ContactNong Yang, MD
Outcome results
None listed